Juno Therapeutics: What The Celgene Potential Acquisition Foretells


  • Celgene Corporation is in the discussion to acquire Juno Therapeutics.
  • Highly favorable M&A environment foretells more acquisitions to come in 2018.
  • It's prudent to take some profits while keeping the rest of one's shares for further upsides.

One, which I mention several times elsewhere, is the need for patience if big profits are to be made from investment. Put another way, it is often easier to tell what will happen to the price of a stock than how much time will elapse before it happens. - The Father of Growth Investing (Philip Fisher)

On Jan. 16, 2017, the bioscience market has reacted with enthusiasm from the news that Celgene Corporation (NASDAQ:NASDAQ:CELG) is in discussion to acquire Juno Therapeutics (NASDAQ:NASDAQ:JUNO). The aforesaid development came a week after the New Jersey-based pharmaceutical giant announced the acquisition of the private firm, Impact BioMedicine. As follows, Juno’s shares traded $23.65 higher at $68 (for over 51% gains for subscribers of Integrated BioSci Investing (“IBI”). At IBI, a good number of our stocks have been acquired over the years. The most notable firm is the leading CAR-T innovators, Kite Pharma (NASDAQ:KITE) that delivered over 82% profits. It was acquired by Gilead Sciences (NASDAQ:GILD) in late 2017. Moreover, it is highly likely that Celgene (NASDAQ:CELG) will be bought out. Furthermore, we also feature other potential M&A candidates for 2018. Of note, the purchasing of companies that delivered the robust run-up is one question. The other inquiry is how should you manage your holdings that deliver substantial gains due to the news leak about an upcoming M&A? In this report, we'll elucidate several viable strategies.

Figure 1: Juno Therapeutics stock chart. (Source: StockCharts)

Fundamentals Analysis

Prior to diving into the portfolio strategy analysis, we wish to provide investors a rundown of the pertinent theme in bioscience - one that is fostering a highly favorable M&A environment that, in and of itself, will play an important role this year. In prior research, we mentioned that large pharmaceutical companies are facing the patent expirations of

Author’s Notes: We’re honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI”) marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics (NASDAQ:NKTR) procured more than 280% profits; Spectrum Pharmaceuticals (NASDAQ:SPPI) delivered over 150% gains; Kite Pharma netted 82%. Exelixis Inc (NASDAQ:EXEL) earned greater than 50% capital appreciation. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.

Notably, we’ll increase our price soon. Subscribe to our marketplace research now to lock in the legacy price and save money in the future. Asides the exclusivities, this article is the truncated version of the research we published in advance to IBI subscribers.

This article was written by

BioSci Capital Partners profile picture
Become an Expert Bio-Investor with the Columbia Doc/Scientist/Market Whiz

Founded by Dr. Harvey Tran MD, MS, CNPR, (in collaboration with other PhDs), Integrated BioSci Investing LLC (“IBI) is a growing community of experts and everyday investors who help one another to invest better.

We bring to you a NEW investment philosophy called “Integrated BioSci Investing.” It's a distillation of value/growth investing wisdom from gurus such as Warren Buffett, Buffet's mentors (Ben Graham and Phil Fischer), and Sir John Templeton that are adapted specifically for biotech stocks.

IBI's analytical research is powered by the integration of (medical, scientific, and market) expertise to deliver unprecedented accuracy in clinical trial forecasting that, in and of itself, is one of the requisites to finding alpha bioscience investment.

Ultimately, our tireless due diligence and the wisdom of IBI members translate into strong returns for you. To name a couple of winners, Crispr Therapeutics (CRSP), CryoPort (CYRX), and Guardant Health (GH), correspondingly delivered 679.1%, 778.3%, and +435.9% for our subscribers."

As an IBI member, you’ll enjoy the following EXCLUSIVE benefits: daily real-time research articles that are comprehensive and more in-depth than free research articles; access to the chat room with many experts and everyday investors for you to ask your questions live about your favorite stocks (you’re expected to get an answer no later than 24 hours); ability to view our high performing portfolios and their pertinent updates; consulting on strategies to help you set up your own portfolios; Our best ideas and their updates via a research article or chat; potential to have research featured on your favorite companies; ability to reach Dr. Tran via phone call or Skype as you wish.

CLICK the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs.

CONNECT with Dr. Tran through his LinkedTree https://linktr.ee/DrHarveyTran

READ more on www.drtranbiosci.com (and make sure to register for our mailing list).

LEARN about Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html

"Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."

Disclosure: I am/we are long ALPN. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (30)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.